Benaroya Research Institute's third annual immunology symposium, New Horizons in Immunity and Disease, took place on Tuesday, May 5, 2026. Due to strong interest and enthusiastic support from the immunology community, we relocated this year’s event to Bell Harbor International Conference Center in Seattle, a larger venue that better accommodated our growing audience.
Once again, we brought together leading voices from the local and national immunology research community for a day of collaboration, discovery, discussion and connection. Building on two years of full houses, dynamic presentations, and meaningful dialogue, this year’s symposium continued that momentum.
Please contact BRI's marketing and communications team via email with any questions.
We look forward to next year's event! Please stay tuned for more information.
BRI Immunology Symposium Speakers
The 2026 program featured two standout keynote speakers, Jay Shendure, MD, PhD, and Phil Greenberg, MD, alongside a strong lineup of nationally and locally recognized researchers from institutions including BRI, the University of Washington, and the Allen Institute for Immunology.
BRI Thanks Our Generous Sponsors
Thank you to our partners, supporters and collaborators for the 2026 event. If you are interested in being a sponsor for next year's program, email the BRI Marketing & Communications department.
News
Recognizing BRI Researcher, LeAnn Nguyen, PhD, for Institute for Translational Immunology Fellowship Award
Read More
Benaroya Research Institute Awarded 16 Million Across 18 Grants in First Half of 2026 to Predict, Prevent, Reverse and Cure Immune System Diseases
Read More
Benaroya Research Institute Appoints New Principal Investigator Edward Irvine, PhD
Read More
Featured Publications
UC-associated autoantibodies to αvβ6 inhibit mucosal TGFβ activation and predispose to intestinal inflammation
bioRxiv
Rhinovirus and interleukin-13 alter DNA methylation in bronchial epithelial cells at asthma loci
ERJ Open Res
Innate Immune Cell and Epithelial Subsets Coordinate Airway Responses to Allergen
Am J Respir Cell Mol Biol
A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trial
Ann Rheum Dis
Type 1 Diabetes Driven by Residual Recipient T Cells After Hematopoietic Cell Transplantation: A Case Report
Diabetes Care
